Abingdon Health (LON: ABDX) shares are trading higher on Friday after the company announced it has signed an exclusive manufacturing agreement with BioSure Limited.
The deal will see Abingdon, a developer and manufacturer of rapid tests, manufacture BioSure's own Covid-19 lateral flow tests.
The contract manufacturing services will utilise lateral flow manufacturing facilities at Abingdon's York and Doncaster sites.
“We are delighted to be supporting BioSure and building on our long-term collaboration with the BioSure team. We are committed to supporting the deployment of these much-needed lateral flow test to the UK and international markets,” commented Chris Yates, CEO of Abingdon Health.
Brigette Bard, CEO of BioSURE, said they are “thrilled to be continuing to build our portfolio of products with Abingdon. BioSure is committed to delivering British developed tests to the global market and Abingdon are our ideal partner to manufacture our world-leading products.”
Abingdon Health's share price is currently trading at 42.6p, up 5.06%.
Should you invest in Abingdon Health shares?
Abingdon Health shares are traded on the London stock exchange's AIM market (the alternative investment market), which is the submarket specifically for smaller companies. AIM stocks are attractive to investors as they have tax advantages and smaller companies have the potential to benefit from rapid growth. But are Abingdon Health shares the best buy? Our stock market analysts regularly review the market and share their picks for high growth companies